Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study
Yıl: 2021 Cilt: 22 Sayı: 1 Sayfa Aralığı: 73 - 77 Metin Dili: İngilizce DOI: 10.4274/imj.galenos.2021.62593 İndeks Tarihi: 16-06-2021
Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study
Öz: Introduction: Multiple myeloma (MM) constitutesapproximately 10% of hematological malignan-cies withabnormal proliferation of plasma cells, which causes anabnormal increase of monoclonal immunoglobulin lightchains. We aim to examine our young myeloma cases’ dataand compare light chain disease with other subtypes, whichare known to have a worse prognosis in all age groups.Methods: Fifty-five MM patients diagnosed and treated betweenJanuary 2010 and 2020 under 60 years old, were analyzedretrospectively. Their demographic data, laboratory, treatmentsubtypes, MM subtypes, CRAB findings (hypercalcemia, renalfailure, anemia, and presence of lytic bone lesions), treatment,and responses to the first-line treatment were analyzed. Thepatients were divided into two groups, the light chain andother myeloma subgroups, and compared statistically.Results: Seventeen patients were female (30.9%), and 38 weremale (69.1%). The median age was 54 (range: 34-59) years. Themedian duration of follow-up was 30 (range: 3-108) months.The MM sub-types examined were: immunoglobulin G (IgG)/Kappa 13 (23.6%), kappa light chain 10 (18.2%), lambda lightchain 10 (18.2%), IgG/Lambda 9 (16.4%), IgA/Lambda 8 (14.5%),and IgA/Kappa 5 (9.1%). There was no significant differencebetween the two groups except for albumin and calciumvalues. In the other myeloma subtype group, albumin andcalcium values were significantly lower (p<0.05) than the lightchain group.Conclusion: The myeloma distribution under the age of 60was different from that in the general my-eloma population.The light chain was more at the forefront, which appears tobe related to lytic le-sions, kidney failure, and amyloidosis.Moreover, albumin, an independent prognostic indicator formyeloma, decreased in the other myeloma subgroup comparedwith the light chain subgroup. They are first mentioned in theliterature in patients under 60 years old
Anahtar Kelime: Altmış Yaş Altı Multipl Miyelom Hastalarında Subgrup Analizi: Tek Merkez Çalışma
Öz: Amaç: Multipl miyelom (MM), hematolojik malignitelerin yaklaşık %10’unu oluşturan; monoklonal immünglobulin artışına eşlik eden serbest hafif zincir salınımına neden olan anormal proliferasyon gösteren, malign plazma hücrelerinin oluşturduğu bir hastalıktır. Çalışmamızda, tanı anında 60 yaş altında olan genç miyelom olgularımızın verilerini, retrospektif olarak ortaya koymayı ve kötü prognoza sahip olduğu bilinen hafif zincir hastalığı ile diğer miyelom alt tiplerini karşılaştırmayı amaçladık. Yöntemler: Ocak 2010 ile Ocak 2020 arasında 60 yaşın altında tanı alarak tedavi edilen elli beş MM hastası retrospektif olarak incelendi. Demografik veriler, laboratuvar parametreleri, tedavi alt tipleri, MM alt tipleri, CRAB bulguları (hiperkalsemi, böbrek yetmezliği, anemi ve litik kemik lezyonlarının varlığı), tedavi ve birinci basamak tedaviye yanıtları analiz edildi. Hastalar hafif zincir ve diğer miyelom alt grupları olarak iki gruba ayrıldı ve istatistiksel olarak aynı başlangıç parametreleri açısından karşılaştırıldı. Bulgular: On yedisi kadın (%30,9) ve 38’i erkek (%69,1) idi. Ortanca yaş 54 bulundu (aralık: 34-59). Medyan takip süresi 30 aydı (aralık: 3-108). MM alt tipleri incelendiğinde; immünoglobulin G (IgG)/Kappa 13 (%23,6), kappa hafif zincir 10 (%18,2), lambda hafif zincir 10 (%18,2), IgG/Lambda 9 (%16,4), IgA/Lambda 8 (%14,5) ve IgA/Kappa 5 (%9,1) idi. Hafif zincir ve diğer miyelom alt grupları istatistiksel olarak karşılaştırıldı. İki grup arasında albümin ve kalsiyum değerleri dışında anlamlı bir farklılık saptanmadı. Diğer miyelom alt tipi grubunda, albümin ve kalsiyum değerleri hafif zincir grubuna göre anlamlı olarak düşüktü (p<0,05). Sonuç: Çalışmamızda 60 yaşın altındaki miyelom dağılımının, genel miyelom popülasyonu ile aynı olmadığı görülmüş olup; litik lezyon, böbrek yetmezliği ve amiloidoz ile daha çok birliktelik gösteren hafif zincir hastalığı daha fazla görülmüştür. Ayrıca miyelom için bağımsız bir prognositik gösterge olarak görülen albümin, diğer miyelom alt grubunda, hafif zincir grubuna göre anlamlı olarak azalmıştı. Bu bulgular 60 yaş altı miyelom olgularında ilk kez ortaya konulmaktadır.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: 538-48.
- 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7-34.
- 3. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046‐60.
- 4. Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol 2016; 43: 676-81.
- 5. Zhang JJ, Sun WJ, Huang ZX, Chen SL, Zhong YP, Hu Y, et al. Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study. World J Surg Oncol 2014; 12: 234.
- 6. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-73.
- 7. Mollee P, Tate J. Monitoring of light chain myeloma - time for a change. Br J Haematol 2017; 178: 177-8.
- 8. Rafae A, Malik MN, Abu Zar M, Durer S, Durer C. An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring. Cureus 2018; 10: e3148.
- 9. Gandolfi S, Prada CP, Richardson PG. How I treat the young patient with multiple myeloma. Blood 2018; 132: 1114-24.
- 10. Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J 2018; 8: 26.
- 11. Pál I, Illés Á, Váróczy L. Multiple Myeloma of the Young - a Single Center Experience Highlights Future Directions. Pathol Oncol Res 2020; 26: 419-24.
- 12. Jurczyszyn A, Nahi H, Avivi I, Gozzetti A, Niesvizky R, Yadlapati S, et al. Characteristics and outcomes of patients with multiple myeloma aged 21- 40 years versus 41-60 years: a multi-institutional case-control study. Br J Haematol 2016; 175: 884-91.
- 13. Giralt S, Seifter E. Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients. Hematology Am Soc Hematol Euc Program 2018; 2018: 103-9.
- 14. Shin J, Koh Y, Youk J, Kim M, Kim BS, Choi CW, et al. Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications. Korean J Intern Med 2017; 32: 722-30.
- 15. Kim JE, Yoo C, Lee DH, Kim SW, Lee JS, Suh C. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. Ann Hematol 2010; 89: 391-7
| APA | SERIN I, Doğu M (2021). Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study. , 73 - 77. 10.4274/imj.galenos.2021.62593 |
| Chicago | SERIN Istemi,Doğu Mehmet Hilmi Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study. (2021): 73 - 77. 10.4274/imj.galenos.2021.62593 |
| MLA | SERIN Istemi,Doğu Mehmet Hilmi Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study. , 2021, ss.73 - 77. 10.4274/imj.galenos.2021.62593 |
| AMA | SERIN I,Doğu M Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study. . 2021; 73 - 77. 10.4274/imj.galenos.2021.62593 |
| Vancouver | SERIN I,Doğu M Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study. . 2021; 73 - 77. 10.4274/imj.galenos.2021.62593 |
| IEEE | SERIN I,Doğu M "Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study." , ss.73 - 77, 2021. 10.4274/imj.galenos.2021.62593 |
| ISNAD | SERIN, Istemi - Doğu, Mehmet Hilmi. "Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study". (2021), 73-77. https://doi.org/10.4274/imj.galenos.2021.62593 |
| APA | SERIN I, Doğu M (2021). Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study. İstanbul Medical Journal, 22(1), 73 - 77. 10.4274/imj.galenos.2021.62593 |
| Chicago | SERIN Istemi,Doğu Mehmet Hilmi Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study. İstanbul Medical Journal 22, no.1 (2021): 73 - 77. 10.4274/imj.galenos.2021.62593 |
| MLA | SERIN Istemi,Doğu Mehmet Hilmi Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study. İstanbul Medical Journal, vol.22, no.1, 2021, ss.73 - 77. 10.4274/imj.galenos.2021.62593 |
| AMA | SERIN I,Doğu M Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study. İstanbul Medical Journal. 2021; 22(1): 73 - 77. 10.4274/imj.galenos.2021.62593 |
| Vancouver | SERIN I,Doğu M Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study. İstanbul Medical Journal. 2021; 22(1): 73 - 77. 10.4274/imj.galenos.2021.62593 |
| IEEE | SERIN I,Doğu M "Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study." İstanbul Medical Journal, 22, ss.73 - 77, 2021. 10.4274/imj.galenos.2021.62593 |
| ISNAD | SERIN, Istemi - Doğu, Mehmet Hilmi. "Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study". İstanbul Medical Journal 22/1 (2021), 73-77. https://doi.org/10.4274/imj.galenos.2021.62593 |
